{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Muscular+Dystrophies&page=2",
    "query": {
      "condition": "Muscular Dystrophies",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Muscular+Dystrophies&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-07T19:32:59.583Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02760264",
      "title": "A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Vamorolone 0.25 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Vamorolone 0.75 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Vamorolone 2.0 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Vamorolone 6.0 mg/kg/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ReveraGen BioPharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "6 Years",
        "sex": "MALE",
        "summary": "4 Years to 6 Years · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2016-06",
      "completion_date": "2018-05-01",
      "has_results": true,
      "last_update_posted_date": "2019-01-02",
      "last_synced_at": "2026-06-07T19:32:59.583Z",
      "location_count": 6,
      "location_summary": "Davis, California • Gainesville, Florida • Orlando, Florida + 3 more",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02760264"
    },
    {
      "nct_id": "NCT03867435",
      "title": "Assessing Clinical Endpoints and Biomarkers in Myotonic Dystrophy Type-1 and Type 2 (ASCEND-DM)",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myotonic Dystrophy Type-1",
        "Myotonic Dystrophy Type-2"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "11 Years to 70 Years"
      },
      "enrollment_count": 4,
      "start_date": "2020-02-24",
      "completion_date": "2021-11-02",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-06-07T19:32:59.583Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03867435"
    },
    {
      "nct_id": "NCT03508947",
      "title": "Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "WVE-210201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wave Life Sciences USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "5 Years to 18 Years · Male only"
      },
      "enrollment_count": 36,
      "start_date": "2018-01-24",
      "completion_date": "2019-03-06",
      "has_results": false,
      "last_update_posted_date": "2019-04-08",
      "last_synced_at": "2026-06-07T19:32:59.583Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03508947"
    },
    {
      "nct_id": "NCT00577577",
      "title": "Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myotonic Dystrophy Type 1"
      ],
      "interventions": [
        {
          "name": "rhIGF-I/rhIGFBP-3",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insmed Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 69,
      "start_date": "2007-12",
      "completion_date": "2008-12-29",
      "has_results": true,
      "last_update_posted_date": "2022-01-06",
      "last_synced_at": "2026-06-07T19:32:59.583Z",
      "location_count": 12,
      "location_summary": "Orange, California • Sacramento, California • Kansas City, Kansas + 9 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00577577"
    },
    {
      "nct_id": "NCT02653833",
      "title": "The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Tadalafil 20 MG",
          "type": "DRUG"
        },
        {
          "name": "beetroot juice extract",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2017-11-01",
      "completion_date": "2018-09-01",
      "has_results": false,
      "last_update_posted_date": "2020-01-14",
      "last_synced_at": "2026-06-07T19:32:59.583Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02653833"
    },
    {
      "nct_id": "NCT02295748",
      "title": "An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Deflazacort",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PTC Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "4 Years and older · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2014-12",
      "completion_date": "2017-08-24",
      "has_results": false,
      "last_update_posted_date": "2017-12-08",
      "last_synced_at": "2026-06-07T19:32:59.583Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02295748"
    },
    {
      "nct_id": "NCT04572893",
      "title": "Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Familial Dilated Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "danicamtiv",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 41,
      "start_date": "2020-08-04",
      "completion_date": "2024-02-22",
      "has_results": true,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-06-07T19:32:59.583Z",
      "location_count": 12,
      "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04572893"
    },
    {
      "nct_id": "NCT04800874",
      "title": "Study of BBP-418 in Patients With LGMD2I",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "LGMD2I"
      ],
      "interventions": [
        {
          "name": "BBP-418",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ML Bio Solutions, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "12 Years to 55 Years"
      },
      "enrollment_count": 14,
      "start_date": "2021-02-18",
      "completion_date": "2026-11-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-08",
      "last_synced_at": "2026-06-07T19:32:59.583Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04800874"
    },
    {
      "nct_id": "NCT02308657",
      "title": "Multicenter Observational Study of Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myotonic Dystrophy Type 1"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 120,
      "start_date": "2013-11",
      "completion_date": "2017-10",
      "has_results": false,
      "last_update_posted_date": "2017-10-26",
      "last_synced_at": "2026-06-07T19:32:59.583Z",
      "location_count": 6,
      "location_summary": "Stanford, California • Gainesville, Florida • Kansas City, Kansas + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02308657"
    },
    {
      "nct_id": "NCT02525302",
      "title": "HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "HT-100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akashi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "20 Years",
        "sex": "MALE",
        "summary": "6 Years to 20 Years · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2015-05",
      "completion_date": "2016-12-30",
      "has_results": false,
      "last_update_posted_date": "2019-03-12",
      "last_synced_at": "2026-06-07T19:32:59.583Z",
      "location_count": 5,
      "location_summary": "Sacramento, California • Baltimore, Maryland • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02525302"
    }
  ]
}